Neumora Therapeutics (NMRA)

• Market cap: $1.66B
• 1 day: 6.52%
• 5 days: 4.15%
• 1 month: -19.04%
• 3 months: -1.63%
• 6 months: 3.63%
• Year to date: -39.11%
• 1 year: -12.65%
• 5 years: -36.68%
• 10 years: -36.68%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.

Employees: 109

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

77% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 13

55% more call options, than puts

Call options by funds: $14.6M | Put options by funds: $9.43M

48% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 23

27% more capital invested

Capital invested by funds: $714M [Q2] → $906M (+$192M) [Q3]

11% more funds holding

Funds holding: 93 [Q2] → 103 (+10) [Q3]

2.67% less ownership

Funds ownership: 45.51% [Q2] → 42.85% (-2.67%) [Q3]

20% less funds holding in top 10

Funds holding in top 10: 5 [Q2] → 4 (-1) [Q3]

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $15 46% upside
• Avg. target: $25 140% upside
• High target: $30 192% upside

7 analyst ratings

• positive: 6 86%
• neutral: 1 14%
• negative: 0 0%

RBC Capital Brian Abrahams 21% 1-year accuracy 13 / 62 met price target	182% upside $29	Outperform Reiterated	22 Nov 2024
HC Wainwright & Co. Douglas Tsao 52% 1-year accuracy 85 / 163 met price target	192% upside $30	Buy Reiterated	13 Nov 2024
Needham Ami Fadia 51% 1-year accuracy 64 / 125 met price target	124% upside $23	Buy Reiterated	13 Nov 2024
JP Morgan Tessa Romero 15% 1-year accuracy 2 / 13 met price target	46% upside $15	Neutral Downgraded	5 Nov 2024
Needham Ami Fadia 51% 1-year accuracy 64 / 125 met price target	124% upside $23	Buy Reiterated	18 Oct 2024